Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma

• Main Authors: Thomas Couronne, Paul Girot, Julien Hadoux, Thierry Lecomte, Alice Durand, Caroline Fine, Katia Vandevoorde, Catherine Lombard-Bohas, Thomas Walter
• Format: Article
• Language: English
• Published: Bioscientifica 2020-06-01
• Series: Endocrine Connections
• Subjects: dacarbazine; temozolomide; alkylating agents; neuroendocrine carcinoma; neuroendocrine tumours
• Online Access: https://ec.bioscientifica.com/view/journals/ec/aop/ec-20-0192/ec-20-0192.xml

Objective: First-line chemotherapy in metastatic neuroendocrine carcinomas (NECs) is based on etoposide and platinum. However, there is no standard concerning second-line treatment. The objective of this study was to evaluate effic acy and tolerance of dacarbazine or temozolomide in metastatic digestive NEC as post first-line treatment. Material and methods: This study included patients with a metastatic NEC of digestive or unknown primary site. All patients received platinum-etoposi de as first-line chemotherapy. Primary endpoint was progression-free survival (PFS). Secondary endpoints were clinical/morphological responses, toxicity, and overall survival (OS). Results: Twenty-seven patients were included: 17 received dacarbazine and 10 temozolomide as post-first line treatments. Median PFS was 3.0 ( 95%CI (2.2;3.7)) months. There was no significant difference between dacarbazine and temoz olomide on PFS. Clinical and morphological responses were found in 12 and 9 pat ients, respectively. Median OS was 7.2 (95%CI (2.2;12.2)) months. The toxicity profil e was that expected with such treatments. Conclusion: LV5FU2-dacarbazine or temozolomide-capecitabine chemotherapies allow a temporary clinical response for almost half of patients and/or a morphological response for a third of patients.